Oxford Biomedica Future Growth
Future criteria checks 1/6
Oxford Biomedica is forecast to grow earnings and revenue by 56.7% and 17.9% per annum respectively. EPS is expected to grow by 57.7% per annum. Return on equity is forecast to be -3% in 3 years.
Key information
56.7%
Earnings growth rate
57.7%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 17.9% |
Future return on equity | -3.0% |
Analyst coverage | Good |
Last updated | 29 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 210 | 4 | 12 | 37 | 4 |
12/31/2025 | 163 | -22 | -10 | -1 | 9 |
12/31/2024 | 130 | -40 | -37 | -25 | 8 |
12/31/2023 | 90 | -89 | -50 | -30 | 7 |
6/30/2023 | 119 | -62 | -9 | 6 | N/A |
3/31/2023 | 130 | -50 | -19 | -3 | N/A |
12/31/2022 | 140 | -39 | -29 | -13 | N/A |
9/30/2022 | 133 | -32 | -31 | -17 | N/A |
6/30/2022 | 126 | -25 | -33 | -21 | N/A |
3/31/2022 | 134 | -3 | -9 | 2 | N/A |
12/31/2021 | 143 | 19 | 16 | 25 | N/A |
9/30/2021 | 139 | 19 | 15 | 26 | N/A |
6/30/2021 | 135 | 19 | 15 | 26 | N/A |
3/31/2021 | 111 | 6 | 2 | 15 | N/A |
12/31/2020 | 88 | -6 | -10 | 3 | N/A |
9/30/2020 | 77 | -9 | -16 | -1 | N/A |
6/30/2020 | 66 | -13 | -22 | -6 | N/A |
3/31/2020 | 65 | -14 | -26 | -5 | N/A |
12/31/2019 | 64 | -16 | -29 | -4 | N/A |
9/30/2019 | 64 | -12 | -26 | -4 | N/A |
6/30/2019 | 64 | -8 | -23 | -4 | N/A |
3/31/2019 | 65 | 0 | -10 | 4 | N/A |
12/31/2018 | 67 | 8 | 3 | 13 | N/A |
9/30/2018 | 62 | 4 | 9 | 18 | N/A |
6/30/2018 | 57 | 0 | 16 | 23 | N/A |
3/31/2018 | 47 | -5 | 8 | 13 | N/A |
12/31/2017 | 38 | -9 | 1 | 3 | N/A |
9/30/2017 | 34 | -10 | -3 | -1 | N/A |
6/30/2017 | 31 | -11 | -7 | -6 | N/A |
3/31/2017 | 29 | -14 | N/A | -4 | N/A |
12/31/2016 | 28 | -17 | N/A | -2 | N/A |
9/30/2016 | 26 | -16 | N/A | -1 | N/A |
6/30/2016 | 24 | -16 | N/A | -1 | N/A |
3/31/2016 | 20 | -15 | N/A | -7 | N/A |
12/31/2015 | 16 | -13 | N/A | -13 | N/A |
9/30/2015 | 15 | -12 | N/A | -12 | N/A |
6/30/2015 | 13 | -10 | N/A | -10 | N/A |
3/31/2015 | 13 | -9 | N/A | -8 | N/A |
12/31/2014 | 14 | -9 | N/A | -6 | N/A |
9/30/2014 | 11 | -9 | N/A | -8 | N/A |
6/30/2014 | 8 | -10 | N/A | -9 | N/A |
3/31/2014 | 7 | -11 | N/A | -10 | N/A |
12/31/2013 | 5 | -11 | N/A | -11 | N/A |
9/30/2013 | 5 | -10 | N/A | -10 | N/A |
6/30/2013 | 5 | -10 | N/A | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OXOA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OXOA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OXOA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OXOA's revenue (17.9% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: OXOA's revenue (17.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: OXOA is forecast to be unprofitable in 3 years.